1 型糖尿病与工程化胰岛移植。
Type 1 diabetes and engineering enhanced islet transplantation.
机构信息
Institute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, Eberhard Karls University Tübingen, 72076 Tübingen, Germany; NMI Natural and Medical Sciences Institute at the University Tübingen, 72770 Reutlingen, Germany.
Institute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
出版信息
Adv Drug Deliv Rev. 2022 Oct;189:114481. doi: 10.1016/j.addr.2022.114481. Epub 2022 Aug 21.
The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community: (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic β-cells, pathology of T1D and current state of β-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective.
治疗 1 型糖尿病(T1D)的新治疗方法的发展依赖于对胰岛素分泌β细胞生物学的精确理解和破译,以及负责其自身免疫破坏的机制。β细胞或胰岛移植被视为数百万糖尿病患者的一种潜在长期治疗方法。为了推进胰岛素分泌细胞移植领域,科学界目前正在研究两个主要的研究领域:(1)确定将干细胞分化为产生胰岛素的细胞的发育途径,提供源源不断的细胞来源;(2)移植策略和工程化移植,以提供对移植细胞的保护和增强其功能。在这篇综述中,我们讨论了胰腺β细胞的生物学、T1D 的病理学以及β细胞分化的现状。我们从转化的角度全面地讨论了不同的可能性,以设计增强的胰岛素分泌细胞/胰岛移植。